Evotec (OTCMKTS:EVTCY) Rating Lowered to Sell at ValuEngine
Separately, Zacks Investment Research upgraded Evotec from a sell rating to a hold rating in a report on Monday, October 21st.
Shares of EVTCY stock opened at $56.48 on Monday. The company has a market cap of $4.36 billion, a price-to-earnings ratio of 68.88 and a beta of 1.20. Evotec has a 52 week low of $40.67 and a 52 week high of $59.50. The company has a quick ratio of 2.97, a current ratio of 3.06 and a debt-to-equity ratio of 0.91. The firm has a 50 day moving average of $53.66 and a 200-day moving average of $47.65.
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.
Further Reading: How is a buy-side analyst different from a sell-side analyst?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.